Interaction of onconase with the human ribonuclease inhibitor protein

Biochemical and Biophysical Research Communications. 2008 Dec 12;377(2):512-4. Epub 2008 Oct 16. [Link] Turcotte RF, Raines RT. Medical Scientist Training Program and Biophysics Graduate Program, University of Wisconsin-Madison, Madison, WI 53706, USA. Abstract One of the tightest known protein–protein interactions in biology is that between members of the ribonuclease A superfamily and the ribonuclease inhibitor…

Read More

The cytotoxic ribonuclease onconase targets RNA interference (siRNA)

Cell Cycle. 2008 Oct;7(20):3258-61. Epub 2008 Oct 25. [Link] Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z. Department of Pathology, Brander Cancer Research Institute, New York Medical College, Valhalla, New York 10595, USA. Abstract Onconase (Onc), a ribonuclease from oocytes of Northern Leopard frogs (Rana pipiens) is cytostatic and cytotoxic to a variety…

Read More

Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity

Current Pharmaceutical Biotechnology. 2008 Jun;9(3):185-9. Link Rutkoski TJ, Raines RT. Department of Biochemistry, University of Wisconsin-Madison, 433 Babcock Drive, Madison, WI 53706 1544, USA. Abstract Onconase® (ONC) is an amphibian member of the bovine pancreatic ribonuclease (RNase A) superfamily that exhibits innate antitumoral activity. ONC has been granted both orphan-drug and fast-track status by the…

Read More

Onconase and Amphinase, the Antitumor Ribonucleases from Rana pipiens Oocytes

Current Pharmaceutical Biotechnology. 2008 Jun;9(3):215-25. Link Ardelt W, Shogen K, Darzynkiewicz Z. Alfacell Corporation, 300 Atrium Drive, Somerset, NJ 08873, USA. wardelt@alfacell.com Abstract Rana pipiens oocytes contain two homologues of pancreatic ribonuclease A that are cytostatic and cytotoxic to human cancer cells. Extensively studied Onconase is in advanced Phase IIIb clinical trials against malignant mesothelioma,…

Read More

Antibody-onconase conjugates: cytotoxicity and intracellular routing

Current Pharmaceutical Biotechnology. 2008 Jun;9(3):226-30. Link Rybak SM. Bionanomics, LLC, 411 Walnut Street, Green Cove Springs, FL 32043, USA. rybak@mindspring.com Abstract Onconase, a member of the pancreatic ribonuclease A superfamily, is currently in Phase III clinical trials for treatment of unresectable malignant mesothelioma. The anticancer effect of onconase may relate to its intracellular target, a…

Read More

Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy

Current Pharmaceutical Biotechnology. 2008 Jun;9(3):231-4. Link Krauss J, Arndt MA, Dübel S, Rybak SM. Natinal center for tumor diseases (NCT), Universit6y of Heidelberg, Im Neuenheimer Fild 350, D-69120 Heidleberg, Germany. juergen.krauss@med.uni-heidelberg.de Abstract Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models…

Read More

A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells

Molecular Cancer Therapeutics. 2008 Jul 7. [Epub ahead of print] [Link] Ramos-Nino ME, Littenberg B. Departments of Pathology and Medicine and Nursing, University of Vermont, Burlington, Vermont. Abstract Accumulating evidence supports the idea that two known phosphatidylinositol 3′-kinase (PI3K) downstream proteins, Fra-1 and Survivin, are potential targets for cancer therapy. Increased expression of Fra-1, a…

Read More

Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy

Expert Opinion on Biological Therapy. 2008 Jun;8(6):813-27. [Link] Assaly M, Bongiovanni M, Kumar N, Egger JF, Pelte MF, Genevay M, Finci V, Tschanz E, Pache JC. Department of Pathology, Geneva University Hospital, Geneva, Switzerland. Abstract Background: Ranpirnase, a cytotoxic amphibian ribonuclease, is effective against cancer cells, inducing apoptosis independently of p53 protein. Onconase® (the smallest…

Read More

Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines

Cancer Biology & Therapy. 2008 Apr 19;7(7) [Epub ahead of print] [Link] Ita M, Halicka HD, Tanaka T, Kurose A, Ardelt B, Shogen K, Darzynkiewicz Z. Brander Cancer Research Institute and Department of Pathology, New York Medical College, Valhalla, NY, 10595; Ita Dental Clinic, Kama-city, Fukuoka 820-0501, Japan. Abstract Onconase (Onc), a ribonuclease from oocytes…

Read More